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Abstract: Despite the widespread availability of effective vaccines, new cases of infection with
severe acute respiratory syndrome coronavirus-2, the cause of coronavirus disease 2019 (COVID-19),
remain a concern in the settings of vaccine hesitancy and vaccine breakthrough. In this randomized,
controlled, phase 2 trial, we hypothesized that high-dose ascorbic acid delivered intravenously to
achieve pharmacologic concentrations may target the high viral phase of COVID-19 and thus improve
early clinical outcomes. Sixty-six patients admitted with COVID-19 and requiring supplemental
oxygen were randomized to receive either escalating doses of intravenous ascorbic acid plus standard
of care or standard of care alone. The demographic and clinical characteristics were well-balanced
between the two study arms. The primary outcome evaluated in this study was clinical improvement
at 72 h after randomization. While the primary outcome was not achieved, point estimates for
the composite outcome and its individual components of decreased use of supplemental oxygen,
decreased use of bronchodilators, and the time to discharge were all favorable for the treatment arm.
Possible favorable effects of ascorbic acid were most apparent during the first 72 h of hospitalization,
although these effects disappeared over the course of the entire hospitalization. Future larger trials of
intravenous ascorbic acid should be based on our current understanding of COVID-19 with a focus
on the potential early benefits of ascorbic in hospitalized patients.
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1. Introduction
In the United States, infection with severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) has led to an estimated 6.2 million hospitalizations and 767,000 deaths due
to coronavirus disease 2019 (COVID-19) [1]. Despite the widespread availability of effective
messenger ribonucleic acid vaccines, new infections remain a concern in the settings of
vaccine hesitancy and vaccine breakthrough [2,3]. Furthermore, as new variants of SARSCoV-2 emerge, such as the Delta variant, there is the risk of infection despite successful

Life 2022, 12, 453. https://doi.org/10.3390/life12030453

https://www.mdpi.com/journal/life

Life 2022, 12, 453

2 of 13

vaccination [4,5]. In these contexts, the development of new treatments for COVID-19
remains a priority.
COVID-19 pneumonia appears to be a two-phase disease, in which the first phase
is dominated by a high viral load in the airways, followed by a later phase of low or
undetectable virus and progressive organizing fibrosis [6]. We hypothesized that high-dose
ascorbic acid (AA) delivered intravenously to achieve pharmacologic concentrations may
target that early high viral phase through two distinct potential mechanisms: Lymphocyte
activation and/or inhibition of early viral replication [7–12]. Both mechanisms are linked
to hydrogen peroxide formation, for which pharmacologic AA concentrations serve as a
prodrug [13–16]. When given intravenously, but not orally, pharmacologic AA concentrations increase the steady-state formation of hydrogen peroxide in vivo over hours in
extracellular fluid but not in the blood [14,15].
To translate potential pharmacologic AA efficacy to acute COVID-19 treatment, we
chose primary and secondary clinical endpoints that reflected these postulated mechanisms
of action. These endpoints included clinical improvement within 72 h of pharmacologic AA
treatment, including hospital discharge, the need for oxygen, the use of bronchodilators,
days of fever, and clinical decline or serious adverse events. Here we present an exploratory,
single-center 2:1 randomized open-label clinical study evaluating these endpoints in 66
people with acute COVID-19 admitted to one hospital system in the United States.
2. Methods
2.1. Study Design and Patients
This study was approved by the Thomas Jefferson University Office of Human Research Institutional Review Board (Protocol #20D.431). It was conducted in accordance
with Federal-Wide Assurance #00002109 to the U.S. Department of Health and Human
Services. Written informed consent was obtained from all patients. The study was registered at ClinicalTrials.gov (Identifier: NCT04363216). This prospective, randomized,
open-label, phase II clinical trial was conducted at Thomas Jefferson University Hospital
and Jefferson Methodist Hospital from 8 May 2020 through 31 December 2020. Potential
study participants were identified based upon hospital admission with a new diagnosis of
SARS-CoV-2. Subjects were screened by study personnel as soon after admission as feasible.
Subjects were considered eligible for inclusion if they were male or a non-pregnant female,
were greater than 18 years of age, were confirmed positive for SARS-CoV-2 infection by
nasal swab, and required supplemental oxygen without an anticipated need for mechanical ventilation within 24 h. Patients were excluded if they had an estimated glomerular
filtration rate less than 50 at the time of screening, known glucose-6-phosphate dehydrogenase deficiency, an anticipated need for mechanical ventilation within 24 h, a home
oxygen requirement, known allergy to AA, or if they were enrolled in another COVID-19
treatment study at the time of enrollment. Patients who met screening requirements were
approached for the study after discussion with their primary inpatient team (see Table S1
for CONSORT checklist).
2.2. Randomization
Once written consent was obtained, patients were randomized, using the REDCap
Randomization Module, in a 2:1 ratio into either a treatment arm that received standard of
care (SoC) plus AA or a control arm that received SoC alone. Randomization was stratified
by risk of complications (high vs. low). Patients were considered high risk if they were
older than 60 or had any of the following comorbidities: Hypertension, structural lung
disease, cardiovascular disease, diabetes, immunocompromising conditions, or conditions
requiring immunosuppressing medications.
2.3. Interventions
If randomized to the treatment arm, patients received routine clinical care plus up to
6 escalating doses of daily AA infusions in magnesium chloride to reduce the sensation of
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burning on injection. On day zero (the randomization day), patients received AA 0.3 g/kg
intravenously once via a continuous 2-h infusion. On day one, patients received AA
0.6 g/kg intravenously once via continuous infusion. Thereafter, patients received 0.9 g/kg
intravenously once daily through day five. Patients received these infusions while they
were admitted. If patients were discharged prior to the final (day five) infusion, AA was
discontinued at the time of discharge. If randomized to the control arm, patients received
routine clinical care.
2.4. Procedures
While enrolled in the study, patients were continuously monitored by the study
coordinator and investigators for adverse and serious adverse events. Patients were
withdrawn if they progressed to a requirement of high-flow oxygen, were transferred to
the intensive care unit, were intubated prior to completion of the study procedures, or if
they developed any clinical condition that raised concerns for safety. An interim safety
analysis was performed after the first 21 patients who were randomized to the treatment
arm completed the course of AA.
2.5. Outcome Measures
The primary endpoint was a composite outcome—clinical improvement at 72 h postrandomization, defined as a 50% reduction in the highest flow rate of oxygen during the
72-h period, a 50% reduction in the most frequent use of bronchodilators within a 12-h
window within the 72-h period, or hospital discharge (whichever came first).
The secondary endpoints analyzed included clinical decline within 36 h of randomization, defined as requiring ICU-level care; the rate of oxygen supplementation given,
defined by the days to a 50% reduction in supplementation during the hospital course; any
day of fever as defined by a temperature of greater than 100.4 ◦ F; the time to discharge; and
serious adverse events specific to the treatment. Adverse and serious adverse events were
defined based upon guidelines set forth on clinicaltrials.gov [17].
2.6. Statistical Analyses
All analyses were prespecified in the trial protocol and followed the intention-to-treat
principle, i.e., included all subjects as randomized. The protocol specified interim analyses
based on the proportion of clinical decline among the first 21 patients in the AA group.
The stopping rule specified that the trial would continue only if fewer than 5 of the first
21 patients experienced clinical decline requiring high-flow oxygen and/or ICU-level care;
this corresponds to the one-sided upper 95% exact binomial confidence limit excluding the
unacceptably high rate of 40%.
The main endpoint (clinical improvement within 72 h from randomization) was
analyzed with a stratified Mantel–Haenszel procedure, with the risk of complication as the
stratification factor. The comparison of the two trial groups was based on a 1-sided exact
test with alpha 0.05; the corresponding 90% exact confidence interval was also computed.
The dichotomous secondary endpoints of any fever and adverse events were analyzed
similarly. The time to a 50% decrease in oxygen supplementation and time to discharge
were analyzed with the Kaplan–Meier method and Cox proportional hazards regression. A
secondary analysis of the time to discharge was performed, also on an intention-to-treat
basis, with adjustments made for admission-to-randomization time.
2.7. Sample Size and Power
With a target sample size of 66 patients (44 in the AA group and 22 in the SoC group),
the trial had 82% power to detect a difference of 60% vs. 25% clinical improvement in the
AA vs. the SoC arm, using the one-sided Fisher’s exact test with alpha 0.05.

2.7. Sample Size and Power
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Figure 1. CONSORT flow diagram.

In regard to demographics and baseline comorbidities, patients were generally balanced between the treatment and control arms (Table 1). The mean age in the treatment
arm was 60 years compared to 61 years in the control arm. Fifty percent of the population
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was female in both groups. At the time of randomization, the mean body mass index was
33.5 in the treatment arm and 35 in the SoC arm.
Table 1. Demographic and clinical characteristics of patients in the treatment and control groups.
Number (%)
Standard of Care
Alone (N = 22)

Ascorbic Acid Plus Standard of Care
(N = 44)

Characteristic
Mean age (SD), years

61 (11)

60 (17)

Age groups, years
<50
50–59
60–69
70+

3 (13.6)
5 (22.7)
10 (45.5)
4 (18.2)

13 (29.5)
7 (15.9)
13 (29.5)
11 (25.0)

Sex
Female
Male

11 (50.0)
11 (50.0)

22 (50.0)
22 (50.0)

Race/Ethnicity
Caucasian/White, Non-Hispanic
African American/Black, Non-Hispanic
Asian, Non-Hispanic
Hispanic
Mean BMI (SD), kg/m2

14 (63.6)
4 (18.2)
1 (4.5)
3 (13.6)
35.0 (8.7)

23 (52.3)
17 (38.6)
2 (4.5)
2 (4.5)
33.5 (8.8)

BMI groups, kg/m2
Normal weight (18.5–24.9)
Overweight (25–29.9)
Obese (30+)

2 (9.1)
5 (22.7)
15 (68.2)

6 (13.6)
11 (25.0)
27 (61.4)

Smoking status
Never smoker
Former smoker
Current smoker

12 (57.1)
9 (42.9)
0 (0.0)

23 (52.3)
17 (38.6)
4 (9.1)

Comorbid conditions
Diabetes
Cardiovascular disease
Chronic obstructive pulmonary disease
Organ transplant recipient

8 (36.4)
12 (54.5)
5 (22.7)
1 (4.5)

15 (34.9)
29 (65.9)
8 (18.6)
0 (0.0)

Risk of complications
Low
High
Mean time since the onset of symptoms
(SD), days

4 (18.2)
18 (81.8)

9 (20.5)
35 (79.5)

7.2 (3.9)

8.1 (3.6)

Medications administered after randomization
Antibiotics
Remdesivir
Glucocorticoids
NSAIDS

2 (9.0)
20 (90.9)
18 (81.8)
11 (50.0)

9 (20.5)
41 (93.2)
33 (75.0)
8 (18.1)

BMI, body mass index; kg/m2 , kilogram per meter squared; NSAIDS, non-steroidal anti-inflammatory drugs; SD,
standard deviation.

The mean time from COVID-19-related symptom onset to randomization was 8.1 days
(standard deviation 3.6) in the treatment arm and 7.2 days (standard deviation 3.9) in
the SoC arm. The baseline oxygen requirement was higher in the SoC arm compared to
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the treatment arm (3 L/min vs. 2.5 L/min, respectively). During the peri-randomization
period, six patients were febrile in the SoC arm, while only one patient was febrile in the
treatment arm. Although baseline clinical characteristics were defined by randomization, the
time from admission to randomization was noted to be longer in the AA group—1.9 days
vs. 1.3 days, respectively. Though there were notable differences in antibiotic and nonsteroidal anti-inflammatory, the current SoC for COVID-19, which includes remdesivir and
corticosteroids, was balanced between the two study arms.
3.2. Interim Analyses
Among the first 21 patients in the AA group, only 2 (9.5%) needed high-flow oxygen
and ICU-level care (upper 95% confidence limit: 27.1%). Therefore, the trial continued to
its full accrual.
3.3. Primary Outcome
The study’s primary outcome was clinical improvement within 72 h of randomization,
based on three components: 50% reduction in oxygen flow rate, 50% reduction in bronchodilator use, or discharge. The results are summarized in Table 2. The point estimate for
overall clinical improvement, as defined by the primary outcome, was larger in the AA arm
compared to the SoC arm (86% vs. 73%; odds ratio, OR = 2.36; 90% confidence interval, CI:
0.66 to 8.07), though the difference was not statistically significant (1-sided p = 0.158). When
adjusted for admission-to-randomization time, the odds ratio for clinical improvement
with treatment was 2.00 (90% CI, 0.57 to 7.00; 1-sided p = 0.219). Furthermore, time of
initiation of the AA treatment did not substantially impact the results; clinical improvement
within 72 h was noted in 19 of the 23 (83%) treatment-arm patients who received their first
infusion within the first 3 h vs. 19 of the 21 (90%) who received their first infusion later.
Table 2. Primary endpoint.
Standard of Care
Alone
(N = 22)

Ascorbic Acid Plus
Standard of Care
(N = 44)

Odds Ratio (90%
Confidence Interval)

p-Value

Number of patients who
achieved clinical improvement
within 72 h of randomization
(N)

16 (72.7%)

38 (86.4%)

2.36 (0.66, 8.07)

0.158

Number of patients who
achieved a 50% reduction in
supplemental oxygen
(N)

15 (68.2%)

34 (77.3%)

Number of patients who
achieved a 50% reduction in
bronchodilator use
(N)

1 (4.5%)

3 (6.8%)

Number of patients discharged
(N)

2 (9.1%)

13 (29.5%)

Regarding the composite endpoint’s components, a 50% decrease in supplemental
oxygen flow rate was observed in 77.3% of individuals in the AA arm compared to 68.2%
of those in the SoC arm. Less than a third of the patients in both groups were using
bronchodilators; among those who were, a 50% reduction in use was noted in 6.8% of the
AA arm vs. 4.5% of the SoC arm. Finally, discharge within 72 h of randomization was 29.5%
in the AA arm vs. 9.1% in the SoC arm.
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3.4. Secondary Outcomes
Table 3 summarizes the results for the secondary endpoints of fever and adverse
events. Fever was less common in the AA group compared to the SoC group (14% vs. 36%;
p = 0.038). However, more patients in the SoC group than in the AA group had fever at
enrollment; when those patients were excluded, the difference between the groups was
attenuated (14% vs. 25%; p = 0.263). Adverse event rates were higher in the AA arm
than in the SoC arm, but the difference was not significant (any adverse event: 55% vs.
32%; p = 0.133; serious adverse events: 18% vs. 9%; p = 0.293). The serious adverse events
included death (one SoC), hypothermia (one AA), hypoxia (six AA, two SoC), leukocytosis
(one AA), pulmonary edema (two AA), and sepsis (two AA). There were no reported
study-related deaths in either arm.
Table 3. Secondary endpoints.
Standard of Care
Alone
(N = 22)

Ascorbic Acid Plus
Standard of Care
(N = 44)

Hazard Ratio (90%
Confidence Interval)

p-Value

Time to 50% reduction in
supplemental oxygen
(days)

2.24

1.87

1.13 (0.65, 1.97)

0.334

Time to discharge (days)

4.65

4.3

1.03 (0.61, 1.76)

0.453

Number of patients with any
fever
(N)

8 (36.4%)

6 (13.6%)

0.28 (0.09, 0.93)

0.038

Number of patients with any
fever, excluding patients with
fever at randomization
(N)

4 (25.0%)

6 (14.0%)

0.50 (0.13, 2.15)

0.263

Any serious adverse event
(N)

2 (9.1%)

8 (18.2%)

2.23 (0.46, 15.5)

0.293

Clinical decline within 36 h of
randomization
(N)

2 (9.1%)

4 (9.1%)

0.95 (0.16, 7.84)

0.643

For the overall study period, the time to a 50% reduction in supplemental oxygenation
was not statistically significant between the AA and SoC arms (median = 1.9 days vs.
2.2 days; hazard ratio (HR) 1.13 [90% CI, 0.65 to 1.97]; p = 0.334) (Figure 2). The time to
discharge was also not statistically different between the two groups (median = 4.3 days
vs. 4.6 days; HR 1.03 [CI 90%, 0.61 to 1.76]; p = 0.453) (Figure 2). Adjustment for the
admission-to-randomization time did not materially change these results; the estimated
hazard ratios were 1.05 (90% CI, 0.60 to 1.85; 1-sided p = 0.432) for the time to a 50%
reduction in oxygen supplementation and 1.03 (90% CI: 0.61 to 1.76; 1-sided p = 0.453) for
the time to discharge. Differences in the cumulative proportion curves for a reduction in
supplemental oxygen and discharge were more pronounced in the first 72 h of the study
(Figure 2, insets). Regarding protocol deviations, as noted in Figure 1, three patients (1 AA,
2 SoC) were incorrectly excluded from the study shortly after consent and randomization
due to clinical deterioration. Notes to file were included in trial documentation.
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Figure 2. Time to a 50% reduction in oxygen supplementation and time to discharge in the study arms.
Figure 2. Time to a 50% reduction in oxygen supplementation and time to discharge in the study
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may serve as an intracellular second messenger in the antiviral activity of lymphocytes [12].
Independent of lymphocyte activation, pharmacologic AA also has direct inhibitory effects
on the replication of some viruses in vitro, presumably via hydrogen peroxide formation [9].
Together, these properties of pharmacologic AA could be harnessed in the early treatment
of COVID-19 pneumonia.
Several trials of AA in COVID-19 patients are in progress or under analysis [18–20], in
addition to a clinical trial of oral AA and zinc in patients with COVID-19 that was stopped
early due to futility [21]. The trial presented here is unique in that it not only examined
intravenous as opposed to oral AA but is also based on the hypothesis-driven mechanism
where pharmacologic ascorbic acid produces hydrogen peroxide in the extracellular fluid.
The data supporting this mechanism of action and clinical dosing application are primarily
from the use of pharmacologic ascorbic acid in cancer treatment. Via hydrogen peroxide
formation, pharmacologic ascorbic acid concentrations selectively target cancer cell death
without harm to normal tissue [14–16,22–25]. The use of the intravenous route was essential
to our study design as oral AA does not produce pharmacologic plasma concentrations of
the vitamin nor does it increase baseline hydrogen peroxide concentrations in extracellular
fluid [13,23]. The dose selected was based on its ability to safely generate maximal hydrogen
peroxide concentrations in vivo in extracellular fluid, utilizing pre-clinical data and data
obtained from patients with malignancies who received intravenous AA treatment.
Intravenous AA has been studied as a sepsis or acute respiratory distress syndrome
(ARDS) therapeutic agent in clinical trials with placebo control and randomization [26–34].
AA was used either as a single agent or in combination with hydrocortisone and/or thiamine. The majority of evidence from these and other studies does not show benefits from
supraphysiologic AA concentrations achieved from the doses used [35,36]. In sepsis studies,
the doses used generally were approximately 25 mg/kg every 6 h, much less than the dose
used here of 0.9 g/kg (900 mg/kg) once daily. Similarly, in sepsis studies, estimated peak
plasma concentrations are predicted to be less than 5% of the peak concentrations predicted
from the dose in our COVID trial [15,23,37]. Doses used in sepsis studies were initially
selected to rapidly reverse AA deficiency unrelated to the generation of hydrogen peroxide,
although the use of even these comparatively lower AA doses in a sepsis population might
confer increased risk because of concurrent acute kidney injury in sepsis [38,39].
Based on our hypotheses, we predicted that the benefit of AA would be most apparent
in the early study period. For this reason, we constructed a primary endpoint of clinical
improvement within 72 h of randomization. The endpoint included three components—a
reduction in supplemental oxygen, a reduction in bronchodilator use, and discharge. At
this stage in our understanding of COVID-19, a reduction in supplemental oxygen use and
discharge remain viable measures of a patient’s clinical course. The Center for Disease
Control and Prevention continues to monitor COVID-19-related ventilatory and discharge
patterns as a component of its National Hospital Care Survey (NHCS) [40]. Furthermore, in
its guideline “COVID-19: Developing Drugs and Biological Products for Treatment and Prevention”, the United States Food and Drug Administration (FDA) recommends the need for
hospitalization and the reduction in supplemental oxygen as important clinical outcomes
to measure in pharmaceutical trials [41]. However, the reduction of bronchodilator use is
not featured in either NHCS data or in the FDA trial recommendations. This likely reflects
our current understanding of the pathophysiology of COVID-19. Bronchodilator use does
not appear to improve clinical outcomes in COVID-19, possibly due to its predilection for
parenchymal and vascular pathology as opposed to airway disease [42].
There was no statistically significant difference between AA and SoC for the primary
endpoint of early clinical improvement. Despite the lack of composite statistical significance, point estimates of the endpoint’s individual components were all supportive of
the treatment arm. As shown in analyses of the secondary endpoints (Table 3, Figure 2),
there were early splits in the cumulative proportion curves for the time to a 50% reduction in oxygenation and the time to discharge. These early potential benefits disappeared
over time. Although these are post-hoc analyses, they hint at a possible advantage to the
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outcomes during the 72-h window after randomization, consistent with our hypotheses.
Further consistent with our hypotheses, these trends were nullified as the curves crossed
later in the hospitalization. As secondary endpoints, both the times to discharge and a 50%
reduction in oxygenation were statistically non-significant when measured over the entire
hospitalization. This pattern was not wholly unexpected. As noted above, an early benefit
was consistent with our proposed mechanism of action.
Regarding safety, the proportion of patients who experienced a clinical decline in the
treatment arm did not meet stopping rules and the trial was continued to its full accrual.
Though the point estimates were higher for serious adverse events and clinical decline
in the first 36 h, the study was not powered to detect these differences, which were not
statistically significant.
Our trial had limitations. In retrospect, the study was small with optimistic outcome
assumptions. Outcomes in this trial were defined in the early part of the pandemic, and
do not reflect our current understanding of COVID-19 as a disease process. Furthermore,
our patient risk stratification, while focused on age and comorbidities, may be improved in
future studies. An emphasis on more severe underlying metabolic disease (i.e., diabetes), as
opposed to any pulmonary or cardiovascular disease, may better improve patient selection
and risk analyses. Viral load and specific analyses of lymphocyte populations were not
feasible for practical and funding limitations, and these data may guide potential future
trials of pharmacologic AA. As has become important both in clinical trials and in clinical
practice, more consideration for symptom onset and baseline inflammatory markers, such
as D-dimer and C-reactive protein, may lead to better correlates for clinical practice. Such
considerations can strengthen future study designs for AA in the treatment of COVID-19.
Although the primary endpoint was not met in this study, trends in supplemental
oxygen use and patient discharge suggest possible clinical signals consistent with the action
of AA at pharmacologic doses. Even at these high doses, there was no statistical difference
in safety between the two study arms. There is a continuing need for early treatment
of COVID-19 in hospitalized patients, and this need will only increase as viral variants
evolve. We believe that future larger studies exploring the use of pharmacologic AA are
warranted and should account for its early disease effects and our evolving understanding
of COVID-19 infection.
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